Prexasertib is a potent inhibitor of both Chk1 and Chk2 [median inhibitory concentration (IC50) of 8 nM for Chk2] but, crucially, has already been used in phase 2 clinical trials in cancer (24). Here, CHEK2 is linked to cancer.